Tjahjadi Robert Tedjasaputra

By Tjahjadi Robert Tedjasaputra, Mochammad Hatta, Muhammad Nasrum Massi, Rosdiana Natzir, Ilhamjaya Patellongi, Marcellus Simadibrata, Rina Masadah, Muhammad Luthfi Parewangi, Prihantono, Andi Asadul Islam, Agussalim Bukhari, Rinda Nariswati, Shirly Elisa Tedjasaputra, Vincent Tedjasaputra and Jonathan Salim

Heterozygote relatives have approximately 80% lifetime colorectal cancer (CRC) risk. mRNA gene expression and Bayesian theorem can calculate CRC’s family risk through the initial pedigree proportion appended with conditional information. The study is the first to report such an application. The present cross-sectional and translational investigation tracked CRC patients’ tissue and blood measurement of adenomatous polyposis coli (APC) and MutS homolog (MSH)2 mRNA quantitative gene expressions, control matching, and ancestral analysis by pedigree and Bayesian theorem. Among 40 CRC patients, mean tissue level and hereditary cutoff of APC are 13,261 (670) fold-change (fc) and 12,195 fc, while 12,219 (756) fc and 11,059 fc for MSH2. A quarter of the CRC patients had a history of familial CRC. Meanwhile, four CRC patients and 10 probands were evaluated for recurrence risk via pedigree, quantitative PCR, and Bayesian analysis. We determined a cutoff point for hereditary mRNA quantitative expression. APC and MSH2 levels in the CRC subjects were significantly lower than controls. The Bayesian analysis builds ways to calculate relative risk in CRC patients’ family members and application in clinical practice.

Part of the book: Gene Expression